AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. ACN
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. NVDA

Go back to AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) Delayed: 250.62 -5.84 (2.28%)
Previous Close $256.46    52 Week High $68.12 
Open $251.84    52 Week Low $50.71 
Day High $254.62    P/E 54.36 
Day Low $248.86    EPS $4.61 
Volume 1,867,990